Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging

Journal of Gastrointestinal Surgery

Volumn 19, Issue 6, 2015, Pages 999-1006

  Lavotshkin, Simon ^a   Jalas, John R ^a   Torisu Itakura, Hitoe ^a   Ozao Choy, Junko ^a   Lee, Ji Hey ^a   Sim, Myung Shin ^c   Stojadinovic, Alexander ^b   Wainberg, Zev ^c   Bifulco, Carlo B ^d   Fox, Bernard A ^e   Bilchik, Anton J ^a,c,f  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EARLE A CHILES RESEARCH INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f California Oncology Research Institute   (United States)

Author keywords

Colon cancer; Immunoprofiling; Recurrence; Staging

Indexed keywords

AGED; CANCER STAGING; CELLULAR IMMUNITY; COLON TUMOR; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOLOGY; MALE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUMOR ASSOCIATED LEUKOCYTE;

AGED; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84930088167     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-015-2759-6     Document Type: Article

References (32)

1. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298: 850–4.
2. Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Annals of surgical oncology 2013;20: 3106–11.
3. Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. Journal of neurosurgery 2011;115: 505–11.
4. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer research 2001;61: 5132–6.
5. Nedergaard BS, Ladekarl M, Thomsen HF, Nyengaard JR, Nielsen K. Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. British journal of cancer 2007;97: 1135–8.
6. Shah W, Yan X, Jing L, Zhou Y, Chen H, Wang Y. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cellular & molecular immunology 2011;8: 59–66.
7. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, Daniele L, Oliaro A. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. The Annals of thoracic surgery 2009;87: 365–71; discussion 71–2.
8. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006;24: 5373–80.
9. Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. American journal of clinical oncology 2013;36: 224–31.
10. Chen KJ, Zhou L, Xie HY, Ahmed TE, Feng XW, Zheng SS. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Medical oncology 2012;29: 1817–26.
11. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313: 1960–4.
12. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009;27: 5944–51.
13. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer research 1998;58: 3491–4.
14. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England journal of medicine 2005;353: 2654–66.
15. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011;29: 610–8.
16. Bilchik A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard R, Elashoff D, Tyler J, Peoples GE, Stojadinovic A. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. Annals of surgery 2010;252: 467–74; discussion 74–6.
17. Bilchik AJ, Hoon DS, Saha S, Turner RR, Wiese D, DiNome M, Koyanagi K, McCarter M, Shen P, Iddings D, Chen SL, Gonzalez M, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Annals of surgery 2007;246: 568–75; discussion 75–7.
18. Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370: 2020–9.
19. Benson AB, 3rd, Hamilton SR. Path toward prognostication and prediction: an evolving matrix. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011;29: 4599–601.
20. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009;27: 3109–16.
21. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010;28: 3219–26.
22. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S, Huguier M, Franc B, Flahault A, Lemoine A, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006;24: 4685–91.
23. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005;23: 3526–35.
24. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011;29: 17–24.
25. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. The Journal of pathology 2014;232: 199–209.
26. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of translational medicine 2012;10: 205.
27. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. The Journal of pathology 2010;222: 350–66.
28. Diederichsen AC, Hjelmborg J, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer immunology, immunotherapy: CII 2003;52: 423–8.
29. Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K, Aoki D. Immunofluorescence-detected infiltration of CD4 + FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 2011;21: 1628–34.
30. Kim HI, Kim H, Cho HW, Kim SY, Song KJ, Hyung WJ, Park CG, Kim CB. The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. Journal of surgical oncology 2011;104: 728–33.
31. Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer immunology, immunotherapy: CII 2010;59: 653–61.
32. Edge SBB, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A., ed AJCC Cancer Staging Manual (ed 7th Edition). New York: Springer; 2010.